Alpha Cognition Inc. Common Stock (ACOG)
Stock · NASDAQ
$8.14as of 10/16/2026
Price chart
Active signals
ACOG Signal Track Record
How signals performed across all stocks →What ACOG's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 15 | 0.0% | 47% | September 16, 2026 |
| Bollinger Band BreakdownActive now | 6 | +11.2% | 83% | September 16, 2026 |
| Bollinger Band Breakout | 6 | -2.6% | 50% | August 7, 2026 |
| Any 20-session window (baseline) | +0.8% | 52% |
Computed by MarketWall from daily closing prices since September 2, 2025. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ACOG
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-se…
- Employees
- 71
- Website
- www.alphacognition.com/
Fundamentals
- 1-day range
- $8.05$8.75
- Market cap
- $188.78M
- P/E (trailing)
- —
- P/E (forward)
- -13.21
- EPS (trailing)
- $-1.09
- Dividend yield
- —
- Beta
- 9.09
- Avg. volume
- 128.0K
Forecasts
5 analyst ratings
Latest news
- Alpha Cognition Says USPTO Published Patent Application Covering Manufacturing Process For Alzheimer’s Drug ZUNVEYLbenzinga · 10/13/2026
- Alpha Cognition to Present New ZUNVEYL® (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall CongressYahoo · 10/6/2026
- Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 10/2/2026
- Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term CareYahoo · 10/1/2026
- Alpha Cognition Announces Data From Its 180-Day Analysis Of Its CONVERGE PRogram For Patients Receiving ZUNVEYL, Donepezil, Galantamine Or RivastigmineBenzinga · 10/1/2026
Insider Activity
Insider Actions →- Opaleye Management Inc. · October 1, 2026 · Buy19.1K @ $8.69
- Opaleye Management Inc. · September 25, 2026 · Buy13.4K @ $8.47
- Opaleye Management Inc. · September 24, 2026 · Buy18.3K @ $8.57
- Opaleye Management Inc. · September 16, 2026 · Buy27.1K @ $8.4
- Opaleye Management Inc. · September 16, 2026 · Buy53.0K @ $8.57
- Opaleye Management Inc. · September 15, 2026 · Buy3.4K @ $8.54
- Opaleye Management Inc. · September 14, 2026 · Buy40.4K @ $8.7
- Robert James Wills · August 21, 2026 · Buy10.0K @ $9.62
- Opaleye Management Inc. · August 3, 2026 · Buy50.0K @ $8
- Opaleye Management Inc. · July 31, 2026 · Buy2.9K @ $7.92
- Opaleye Management Inc. · July 24, 2026 · Buy130 @ $7.9
- Opaleye Management Inc. · July 23, 2026 · Buy49.8K @ $7.8
- Opaleye Management Inc. · July 22, 2026 · Buy10.0K @ $7.83
- Opaleye Management Inc. · July 22, 2026 · Buy140.2K @ $7.83
- Opaleye Management Inc. · June 15, 2026 · Buy4.5K @ $5.99
Institutional Ownership
March 31, 2026
- Total shares held
- 10.51M
- Total value held
- $57.71M
- Institutional holders
- 24
- Unknown2.56M
- Unknown1.92M
- Unknown1.67M
- Unknown1.38M
- Unknown1.06M
- Unknown567.6K
- Unknown365.0K
- Unknown256.4K
- Unknown218.5K
- Unknown188.6K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Alpha Cognition Releases 180-Day Data on CONVERGE Program
Alpha Cognition has published results from a 180‑day study of its CONVERGE program. The data covers patients who are taking ZUNVEYL, donepezil, galantamine or rivastigmine. The release gives a clearer view of how the program performs in real‑world use. Investors can use the information to assess the company’s therapeutic strategy.
Alpha Cognition Releases 180-Day Data on CONVERGE Program. Alpha Cognition has published results from a 180‑day study of its CONVERGE program. The data covers patients who are taking ZUNVEYL, donepezil, galantamine or rivastigmine. The release gives a clearer view of how the program performs in real‑world use. Investors can use the information to assess the company’s therapeutic strategy.